Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Selumetinib

Last Updated: 03/28/17

Status: Currently a NF2 Clinical Trial

Index

  • NF2 Related Trials
  • Treatment Information
  • Also Treatment For
  • Patents

Selumetinib (AZD6244) is a drug being investigated for the treatment of various types of cancer, for example non-small cell lung cancer (NSCLC). - Wikipedia

Trade Name N/A
Other Names AZD 6244, 606143-52-6, AZD6244, AZD-6244, ARRY-142886, CHEMBL1614701, NCGC00189073-01, PubChem21092, Selumetinib (USAN/INN)
Pharmaceutical Company N/A
Inhibitor MAPK/ERK Pathway
Selumetinib blocks the subtypes MEK1 and MEK2 of the MAPK kinase (MEK) enzyme.
Molecular Formula C17H15BrClFN4O3
IUPAC 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
ChemSpider 8303141 (accessed 16:29, Oct 11, 2012)
PubChem CID 10127622

Treatment Information

UK Treatments: The role of insulin-like growth factors signaling in merlin-deficient human schwannomas


Also Treatment For

  • Thyroid Cancer
  • Melanoma
  • Colorectal Cancer
  • Ovarian Cancer

Patents

Top 5 of 19 Treatments
Patent # Date Title
US20100260714A1 6-4-2012 COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF
US20100267793A1 6-4-2012 METHOD OF TREATMENT USING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS METHOD OF TREATMENT USING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20100261718A1 5-14-2012 N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20100261717A1 8-22-2011 N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20100267710A1 7-4-2011 N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS